Shanghai Sonyt Biotechnology co, Ltd se youn nan dirijan manifaktirè yo ak founisè nan cas 254110-79-7 cef27, epstein-barrvirusbrlf-1lytic (148-156) nan Lachin, tou sipòte sèvis koutim. Byenveni nan an gwo en meyè kalite cas 254110-79-7 cef27, epstein-barrvirusbrlf-1lytic (148-156) nan faktori nou an. Kontakte nou pou plis detay.
| Deskripsyon | EBV litik imedyat-bonè BRLF-1 résidus 148–156, yon epitop CD8+ ki limite HLA; itilize pou siveyans reyaktivasyon EBV ak ELISPOT. |
Tablo Enfòmasyon Debaz pwodwi
| Non estanda pwodwi angle | Pwodwi Abreviyasyon / Alias | Fonksyon Tags (separe ak vigil) | Estrikti Nwayo | Fòmil molekilè | Mas egzak (Da) | Mwayèn MW (Da) | Fòm sèl | Longè (aa) |
| CEF27, EBV BRLF-1 litik (148-156) Peptid (RVRAYTYSK, HLA-A*03:01-restriksyon, CAS 254110-79-7) | CEF27; EBV BRLF1/Rta 148-156; RVRAYTYSK; EBV litik-faz CD8+ epitop selil T; CEF peptide pisin eleman #27; R&D PP50756; Molnova M29966; CAS 254110-79-7 | Epitop EBV, pisin peptide CEF, CD8+ epitop selil T, HLA-A*03:01, faz litik, tetramer, siveyans iminite viral, siveyans iminite selil T | Lineyè 9-mer, H-Arg-Val-Arg-Ala-Tyr-Thr-Tyr-Ser-Lys-OH (RVRAYTYSK); sòti nan viris Epstein-Barr imedyat-bonè litik transactivator BRLF1 (Rta, UniProt P03209, EBV B95-8; nòt: PA P03213, ki se pwoteyin pòtal BBRF1) résidus 148-156; eleman #27 nan CEF (CMV/EBV/Grip) CD8+ T-selil epitop peptide pisin, HLA-A*03:01-restriksyon CD8+ T-selil epitop; gen 2x Tyr (pozisyon 5, 7) - pwoteje kont limyè; pa gen Cys/Met/Trp; 2x Arg bay yon karaktè debaz | C51H82N16O14 | 1142.62 | 1143.31 | Pa espesifye (peptide sentetik yo apwovizyone regilyèman kòm sèl TFA, final COA genyen; fòmil peptide gratis C51H82N16O14, MW 1142.62/1143.31; CAS 254110-79-7 yo toujou asiyen nan peptide gratis sa a RVRAYTYSK atravè sous endepandan) | 9 |
Solibilite fizikochimik & Paramèt Depo
| Kòd pwodwi | Aparans | Depo alontèm | Depo kout tèm | Solisyon Estabilite | Estabilite solid poud |
| PEP-CEF27-01 | Poud blan ak blan (estanda pou peptides sentetik) | Store at -20°C, sealed, light-protected and dry, >= 2 ane (pa founisè); gen 2x Tyr - kenbe limyè-pwoteje (amber flakon / FOIL) kont foto-oksidasyon; kenbe imidite-prèv; aliquot pòsyon yon sèl itilize pou evite repete friz-dekonjle | Sere nan 2-8 degre, sele, pwoteje limyè ak sèk, pou apeprè . 2 semèn; apre ouvèti kenbe nan yon desiccator epi peze rapidman; travay aliquots limyè-pwoteje nan -20 degre; bato sou pake glas | Idrofob 9-mer ak solubilite dlo limite: prepare yon stock DMSO 5-10 mg / mL, Lè sa a, delye ak PBS / mwayen kilti nan travay konsantrasyon (souvan 1-10 ug / mL, apeprè . 1-10 uM); gen 2x Tyr - kenbe limyè-pwoteje; pa gen okenn Cys / Met / Trp - pa gen okenn kondisyon anti-oksidasyon; filtre-sterilize nan 0.22 um; pèmèt yo rive nan tanperati chanm anvan ou louvri; magazen DMSO aliquots limyè-pwoteje nan -20 degre epi prepare solisyon k ap travay fre | solid stable >= 2 ane nan -20 degre, sele, limyè pwoteje ak sèk (done founisè); gen 2x Tyr - pwoteje kont limyè; pa gen okenn Cys/Met/Trp - pa gen okenn ajan rediksyon oswa gaz inaktif ki nesesè; kenbe sèk ak limyè-pwoteje apre ouvèti |
Deskripsyon Fonksyonèl
| Kòd pwodwi | Frontend Kout Rezime | Deskripsyon Fonksyon Byolojik detaye | Zòn rechèch aplikab yo (separe ak vigil) | Objektif / Reseptè |
| PEP-CEF27-01 | CEF27 (EBV BRLF1/Rta 148-156, RVRAYTYSK, CAS 254110-79-7), the HLA-A*03:01-restricted EBV lytic-phase CD8+ T-cell epitope, purity >98% (HPLC), yo itilize pou siveyans iminitè T-selil espesifik EBV, eksitasyon pisin CEF ak preparasyon tetramer. | RVRAYTYSK, a nonapeptide at residues 148-156 of the Epstein-Barr virus (EBV B95-8) immediate-early lytic transactivator BRLF1 (Replication and transcription activator, Rta; UniProt P03209, 605 aa - note the correct accession is P03209, whereas P03213 is the BBRF1 portal protein), is component #27 of the CEF (CMV/EBV/Influenza) CD8+ T-cell epitope peptide pool and is confirmed by R&D Systems (PP50756) and Molnova (M29966) as an HLA-A*03:01-restricted epitope (note: NOT HLA-A*02:01; the confusable candidate YVLDHLIVV belongs to Rta 28-37, i.e. CEF14 DYCNVLNKEF, and is unrelated to this product). CAS 254110-79-7 is consistently assigned to this peptide across 6 independent supplier/MSDS sources; Molnova lists purity >98% (HPLC) and >= 2 ane estabilite nan -20 degre. Lajman itilize pou: (1) eksitasyon vitro ak ekspansyon EBV-espesifik CD 8+ selil T (kòm yon eleman pisin CEF); (2) pMHC-I (HLA-A * 03:01) asanble tetramer ak deteksyon flow-cytometric; (3) siveyans iminitè selil T espesifik EBV nan pòtè ki an sante ak pasyan transplantasyon; (4) etid sou iminite selilè faz litik EBV ak reyaktivasyon viral. Remake byen distenksyon ki genyen ant CEF14 deja okipe (Rta 28-37, DYCNVLNKEF, HLA-A * 24:02) ak EBV-BRLF1-134-142 (ATIGTAMYK) - diferan segman nan BRLF1 ak restriksyon HLA diferan. | Siveyans selil T espesifik pou EBV, eksitasyon pisin peptide CEF, epitop CD8+ T-selil, HLA-A*03:01 tetramer, rechèch iminite viral, siveyans reyaktif EBV apre transplantasyon, repons iminitè faz litik. | HLA-A*03:01 (MHC-I) prezante epitop EBV BRLF1/Rta 148-156 nan selil T CD8+ epitop espesifik yo |
Baj popilè: cas 254110-79-7 cef27, epstein-barrvirusbrlf-1lytic (148-156), Lachin cas 254110-79-7 cef27, epstein-barrvirusbrlf-1lytic (148-156) manifaktirè, founisè, faktori
